BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Breast Cancer: HR+/HER2- Disease Coverage

October 16, 2018

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is defined by the overexpression of estrogen or progesterone receptors, or both, and a lack of HER2 expression. Overexpression of hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Endocrine therapy remains the standard treatment for advanced HR+/HER2- breast cancer, with steroidal and non-steroidal aromatase inhibitors making up the most common treatment choices.

This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
Indications Covered: Breast Cancer
Back to the top Back to the top